| [1] |
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. |
| [2] |
Scheck MK, Hofheinz RD, Lorenzen S. 2024. HER2-positive gastric cancer and antibody treatment: state of the art and future developments. |
| [3] |
Kim WH, Gomez-Izquierdo L, Vilardell F, Chu KM, Soucy G, et al. 2018. HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study. |
| [4] |
Luchini C, Brosens LAA, Wood LD, Chatterjee D, Shin JI, et al. 2021. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. |
| [5] |
Kim JY, Shin NR, Kim A, Lee HJ, Park WY, et al. 2013. Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. |
| [6] |
Kang JU, Koo SH. 2011. Assessment of the beneficial loci and prognostic implications of microsatellite instability in gastric carcinoma. |
| [7] |
Zhang Z, Huang J, Li Y, Yan H, Xie J, et al. 2024. Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer. |
| [8] |
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. |
| [9] |
Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, et al. 2013. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. |
| [10] |
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, et al. 2023. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. |
| [11] |
Lee V, Murphy A, Le DT, Diaz LA. 2016. Mismatch repair deficiency and response to immune checkpoint blockade. |
| [12] |
Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, et al. 2021. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. |
| [13] |
Kim ST, Klempner SJ, Park SH, Park JO, Park YS, et al. 2017. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. |
| [14] |
Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, et al. 2016. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. |
| [15] |
Bermúdez A, Arranz-Salas I, Mercado S, López-Villodres JA, González V, et al. 2021. Her2-positive and microsatellite instability status in gastric cancer-clinicopathological implications. |
| [16] |
Yuan Q, Deng D, Pan C, Ren J, Wei T, et al. 2022. Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. |
| [17] |
Zayac A, Almhanna K. 2020. Esophageal, gastric cancer and immunotherapy: small steps in the right direction? |
| [18] |
Lee SM, Oh H. 2024. Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma. |
| [19] |
Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, et al. 2018. HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3. |
| [20] |
Lv H, Zhang J, Sun K, Nie C, Chen B, et al. 2021. Corrigendum: expression of human epidermal growth factor receptor-2 status and programmed cell death protein-1 ligand is associated with prognosis in gastric cancer. |
| [21] |
Shahin M, Patra S, Purkait S, Kar M, Das Majumdar SK, et al. 2024. PD-L1 expression in colorectal carcinoma correlates with the immune microenvironment. |
| [22] |
Dugger SA, Platt A, Goldstein DB. 2018. Drug development in the era of precision medicine. |
| [23] |
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, et al. 2024. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. |
| [24] |
Ma X, Chen J, Huang B, Fu S, Qu S, et al. 2023. ErbB2-upregulated HK1 and HK2 promote breast cancer cell proliferation, migration and invasion. |
| [25] |
Cheng X. 2024. A comprehensive review of HER2 in cancer biology and therapeutics. |
| [26] |
Pous A, Notario L, Hierro C, Layos L, Bugés C. 2023. HER2-positive gastric cancer: the role of immunotherapy and novel therapeutic strategies. |
| [27] |
Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, et al. 2025. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. |
| [28] |
Wang B, Li F, Zhou X, Ma Y, Fu W. 2019. Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis. |